Clinical Features and Prognosis of Ocular Myasthenia Gravis Patients with Different Phenotypes

IntroductIon Myasthenia gravis (MG) is an autoimmune neuromuscular disorder caused by anti‐acetylcholine receptor antibodies (AChR‐Abs) or other etiologies. Ocular symptoms were the first presentations in 40–50% of MG patients. Ptosis and diplopia were the most common symptoms of ocular MG (OMG). Limited studies demonstrated that patients presented with initial symptoms of only ptosis in 47%, only diplopia in 14% and both ptosis and diplopia in 39% of OMG.[1] Variations of diplopia or ptosis did not significantly affect the physical or mental status of OMG. Initial presentation of concurrent ptosis and diplopia was significantly associated with insensitivity to pyridostigmine for OMG patients. However, the differences of clinical features including age of disease onset, gender, thymoma, as well as other autoimmune disease between various phenotypes of OMG remain unidentified.